To conduct a study on the prevalence of cholestatic liver disorders in women.
Summary
HB966 requires the Ohio Department of Health to conduct a one-year statewide study on cholestatic liver disorders in women ages 35 through 45 who are enrolled in Medicaid. The study would focus on disorders associated with increased risk of end-stage liver disease and would collect information on demographics, genetic predispositions, pre-existing conditions such as autoimmune and metabolic disorders, lifestyle risk factors, and the extent to which high-risk participants do not follow through with referrals or treatment recommendations.
After the study period, the Department must prepare a written report analyzing the data and offering recommendations to increase awareness, screening, and genetic testing for cholestatic liver disorders. The report must also examine strategies and funding options to expand screening and genetic testing, including public-private partnerships to support research and testing infrastructure. The report is due to the General Assembly by December 31, 2028, and the study ends upon submission of the report.
Impact
The bill does not directly change substantive health-care coverage or treatment requirements in state law; instead, it directs the Department of Health to gather data and produce policy recommendations that could inform future legislation, public health initiatives, or funding decisions. It would create a temporary state study focused on a specific Medicaid population and require the Department to handle all collected and reported information in compliance with applicable state and federal privacy laws.
Sentiment
Because the bill was only introduced and has no recorded committee testimony or votes, there is no documented legislative debate to gauge support or opposition. On its face, the measure appears to be framed as a public health research and awareness effort, suggesting a generally informational and preventive policy approach rather than a controversial regulatory change.
Contention
The main potential points of contention are likely to involve the scope and cost of the study, the use of Medicaid-enrolled women as the target population, and the collection of sensitive health and genetic information. Any discussion of follow-on recommendations for expanded screening, genetic testing, and public-private partnerships could also raise questions about funding, privacy, and whether the state should prioritize this condition over other health concerns. No specific objections or supporters are identified in the available record.